{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-052344","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.524365+00:00","generated_at":"2026-06-18T22:28:50.868208+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Phathom reports Q4 net loss $55M; FDA meeting in March for vonoprazan resubmission","bullets":["Net loss Q4 2022 $55.0M vs $35.8M Q4 2021; full year net loss $197.7M vs $143.9M.","Cash $155.4M at Dec 31, 2022; additional $100M available under Hercules term loan.","FDA meeting scheduled March 2023 to discuss stability data and resubmission for erosive GERD and H. pylori NDAs.","Positive Phase 3 PHALCON-NERD-301 met primary endpoint (p<0.0001) for vonoprazan in non-erosive GERD.","Commercial launch on hold due to nitrosamine impurity; mitigation measures in place."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-052344","json":"https://secwatch.observer/filing/0001193125-23-052344.json","markdown":"https://secwatch.observer/filing/0001193125-23-052344.md","text":"https://secwatch.observer/filing/0001193125-23-052344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523052344/0001193125-23-052344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523052344/d413841d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:28:50.868208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"884a2d7c5c70230a22704d5bd1fc48c6e7a65bdc","claim":"Phathom Pharmaceuticals, Inc. reported the quarter and year ended December 31, 2022 results: net income Net loss for the fourth quarter ended December 31, 2022 was $55.0 million.","evidence_excerpt":"On February 28, 2023, Phathom Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523052344/0001193125-23-052344-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the fourth quarter ended December 31, 2022 was $55.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}